PFIZER2023-07-012023-09-30 PFIZER2023-07-012023-09-30 PFIZER2023-07-012023-09-30in-bse-fin:OneOperatingExpenses01Member PFIZER2023-07-012023-09-30in-bse-fin:FourOperatingExpenses01Member PFIZER2023-09-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 500680 PFIZER NA Pfizer Limited Equity 2023-04-01 2024-03-31 2023-10-28 2023-10-18 INR Crores Half yearly 12:30:00 15:15:00 2023-10-28 2023-10-28 true Cash Flow Indirect Not applicable Single segment Pharmaceuticals 2023-07-01 2023-09-30 Unaudited Standalone 5752100000.00 360700000.00 6112800000.00 837800000.00 791300000.00 418600000.00 898000000.00 27300000.00 154300000.00 980300000.00 4107600000.00 2005200000.00 0.00 2005200000.00 473400000.00 42200000.00 515600000.00 0.00 1489600000.00 0.00 0.00 0.00 0.00 1489600000.00 -8300000.00 1481300000.00 0.00 0.00 457500000.00 10 32.56 32.56 0.00 0.00 32.56 32.56 1.The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its Meeting held on October 28, 2023 and were approved and taken on record at the Meeting of the Board of Directors of the Company held on that date. 2.The financial results of the Company have been prepared in accordance with Indian Accounting Standards (‘Ind AS”) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time). 3. The financial results for the quarter ended September 30, 2023 have been subject to limited review by the statutory auditors of the Company. The limited review report does not contain any modifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company’s website - www.pfizerltd.co.in 4. During the quarter ended June 30, 2023 the Company, based on the recommendation from Astral SteriTech Private Limited (“Astral”) and out of an abundance of caution, had a voluntarily recall for all the batches of Magnex, Magnamycin and Zosyn manufactured by Astral and marketed / distributed by Pfizer Limited. The said products recorded a sale of `139.25 crore during the year ended March 31, 2023. 5.Net exceptional items aggregating Rs.33.00 crore for the year ended March 31, 2023 includes: a. Income of Rs. 67.12 crore on account of sale of Business undertaking at Thane together with its related business assets and liabilities during the quarter ended March 31, 2023. b. Charge of Rs. 86.71 crore on account of re-evaluation and reassessment of the risk relating to the Company’s old pending VAT / CST litigations, during the quarter ended March 31, 2023. c. Income of Rs. 188.92 crore on account of transfer of certain primarily off patented and generic established medicines business (Upjohn Business) as a going concern together with its related business assets and liabilities during the quarter ended September 30, 2022. d. Charge of Rs. 129.85 crore on account of Voluntary Retirement Scheme (VRS) and an additional charge of Rs. 6.48 crore (net) on account of restructuring to drive business transformation during the quarter ended June 30, 2022. 6.The shareholders in its Annual General Meeting held on August 18, 2023 had approved a final dividend of Rs. 35 (350%) per equity share of Rs.10 each and a special dividend of Rs. 5 (50%) per equity share of ` 10 each for the financial year ended March 31, 2023. The said dividend was paid on September 15, 2023. 7.The Company has only one segment which is ‘Pharmaceuticals’. Therefore disclosure relating to segments is not applicable and accordingly not made. Single segment 2023-04-01 2023-09-30 Unaudited Standalone 11065700000.00 695300000.00 11761000000.00 1698900000.00 2260300000.00 247500000.00 1833200000.00 56000000.00 309800000.00 2092600000.00 8498300000.00 3262700000.00 0.00 3262700000.00 807700000.00 30100000.00 837800000.00 0.00 2424900000.00 0.00 0.00 0.00 0.00 2424900000.00 -16500000.00 2408400000.00 0.00 0.00 457500000.00 10 53.00 53.00 0.00 0.00 53.00 53.00 Other Expenses 980300000.00 Other Expenses 2092600000.00 1639200000.00 93800000.00 0.00 5274900000.00 392600000.00 0.00 0.00 0.00 0.00 0.00 0.00 133800000.00 133800000.00 952200000.00 6081200000.00 14567700000.00 3990800000.00 0.00 1735100000.00 157800000.00 18763800000.00 0.00 162200000.00 20818900000.00 367100000.00 25176800000.00 317500000.00 0.00 40062000000.00 457500000.00 32272400000.00 32729900000.00 32729900000.00 0.00 0.00 733500000.00 733500000.00 457400000.00 0.00 0.00 0.00 1190900000.00 25000000.00 2342800000.00 865800000.00 3233600000.00 333200000.00 932200000.00 1642200000.00 0.00 6141200000.00 7332100000.00 40062000000.00 0.00 186100000.00 -224800000.00 0.00 141300000.00 0.00 0.00 0.00 0.00 171300000.00 0.00 0.00 -577500000.00 309800000.00 0.00 -65300000.00 0.00 0.00 0.00 0.00 0.00 647000000.00 78500000.00 0.00 0.00 0.00 0.00 35700000.00 0.00 -591900000.00 2670800000.00 0.00 0.00 0.00 773300000.00 0.00 1897500000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 100000.00 128200000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 654200000.00 0.00 -546600000.00 0.00 -20500000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 247200000.00 1838000000.00 0.00 0.00 0.00 -2085200000.00 -208200000.00 0.00 -208200000.00 366000000.00 157800000.00 11000000.00 22000000.00 -2700000.00 -5500000.00